Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
25 02 2021
Historique:
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 17 3 2021
Statut: epublish

Résumé

Diet plays a major role in the aetiology of cardiovascular disease (CVD) and as a modifiable risk factor is the focus of many prevention strategies. Recently vegan diets have gained popularity and there is a need to synthesise existing clinical trial evidence for their potential in CVD prevention. To determine the effectiveness of following a vegan dietary pattern for the primary and secondary prevention of CVD. We searched the following electronic databases on 4 February 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and Web of Science Core Collection. We also searched ClinicalTrials.gov in January 2021. We applied no language restrictions. We selected randomised controlled trials (RCTs) in healthy adults and adults at high risk of CVD (primary prevention) and those with established CVD (secondary prevention). A vegan dietary pattern excludes meat, fish, eggs, dairy and honey; the intervention could be dietary advice, provision of relevant foods, or both. The comparison group received either no intervention, minimal intervention, or another dietary intervention. Outcomes included clinical events and CVD risk factors. We included only studies with follow-up periods of 12 weeks or more, defined as the intervention period plus post-intervention follow-up. Two review authors independently assessed studies for inclusion, extracted data and assessed risks of bias. We used GRADE to assess the certainty of the evidence. We conducted three main comparisons: 1. Vegan dietary intervention versus no intervention or minimal intervention for primary prevention; 2. Vegan dietary intervention versus another dietary intervention for primary prevention; 3. Vegan dietary intervention versus another dietary intervention for secondary prevention. Thirteen RCTs (38 papers, 7 trial registrations) and eight ongoing trials met our inclusion criteria. Most trials contributed to primary prevention: comparisons 1 (four trials, 466 participants randomised) and comparison 2 (eight trials, 409 participants randomised). We included only one secondary prevention trial for comparison 3 (63 participants randomised). None of the trials reported on clinical endpoints. Other primary outcomes included lipid levels and blood pressure. For comparison 1 there was moderate-certainty evidence from four trials with 449 participants that a vegan diet probably led to a small reduction in total cholesterol (mean difference (MD) -0.24 mmol/L, 95% confidence interval (CI) -0.36 to -0.12) and low-density lipoprotein (LDL) cholesterol (MD -0.22 mmol/L, 95% CI -0.32 to -0.11), a very small decrease in high-density lipoprotein (HDL) levels (MD -0.08 mmol/L, 95% CI -0.11 to -0.04) and a very small increase in triglyceride levels (MD 0.11 mmol/L, 95% CI 0.01 to 0.21). The very small changes in HDL and triglyceride levels are in the opposite direction to that expected. There was a lack of evidence for an effect with the vegan dietary intervention on systolic blood pressure (MD 0.94 mmHg, 95% CI -1.18 to 3.06; 3 trials, 374 participants) and diastolic blood pressure (MD -0.27 mmHg, 95% CI -1.67 to 1.12; 3 trials, 372 participants) (low-certainty evidence). For comparison 2 there was a lack of evidence for an effect of the vegan dietary intervention on total cholesterol levels (MD -0.04 mmol/L, 95% CI -0.28 to 0.20; 4 trials, 163 participants; low-certainty evidence). There was probably little or no effect of the vegan dietary intervention on LDL (MD -0.05 mmol/L, 95% CI -0.21 to 0.11; 4 trials, 244 participants) or HDL cholesterol levels (MD -0.01 mmol/L, 95% CI -0.08 to 0.05; 5 trials, 256 participants) or triglycerides (MD 0.21 mmol/L, 95% CI -0.07 to 0.49; 5 trials, 256 participants) compared to other dietary interventions (moderate-certainty evidence). We are very uncertain about any effect of the vegan dietary intervention on systolic blood pressure (MD 0.02 mmHg, 95% CI -3.59 to 3.62)  or diastolic blood pressure (MD 0.63 mmHg, 95% CI -1.54 to 2.80; 5 trials, 247 participants (very low-certainty evidence)). Only one trial (63 participants) contributed to comparison 3, where there was a lack of evidence for an effect of the vegan dietary intervention on lipid levels or blood pressure compared to other dietary interventions (low- or very low-certainty evidence). Four trials reported on adverse events, which were absent or minor. Studies were generally small with few participants contributing to each comparison group. None of the included studies report on CVD clinical events. There is currently insufficient information to draw conclusions about the effects of vegan dietary interventions on CVD risk factors. The eight ongoing studies identified will add to the evidence base, with all eight reporting on primary prevention. There is a paucity of evidence for secondary prevention.

Sections du résumé

BACKGROUND
Diet plays a major role in the aetiology of cardiovascular disease (CVD) and as a modifiable risk factor is the focus of many prevention strategies. Recently vegan diets have gained popularity and there is a need to synthesise existing clinical trial evidence for their potential in CVD prevention.
OBJECTIVES
To determine the effectiveness of following a vegan dietary pattern for the primary and secondary prevention of CVD.
SEARCH METHODS
We searched the following electronic databases on 4 February 2020: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and Web of Science Core Collection. We also searched ClinicalTrials.gov in January 2021. We applied no language restrictions.
SELECTION CRITERIA
We selected randomised controlled trials (RCTs) in healthy adults and adults at high risk of CVD (primary prevention) and those with established CVD (secondary prevention). A vegan dietary pattern excludes meat, fish, eggs, dairy and honey; the intervention could be dietary advice, provision of relevant foods, or both. The comparison group received either no intervention, minimal intervention, or another dietary intervention. Outcomes included clinical events and CVD risk factors. We included only studies with follow-up periods of 12 weeks or more, defined as the intervention period plus post-intervention follow-up.
DATA COLLECTION AND ANALYSIS
Two review authors independently assessed studies for inclusion, extracted data and assessed risks of bias. We used GRADE to assess the certainty of the evidence. We conducted three main comparisons: 1. Vegan dietary intervention versus no intervention or minimal intervention for primary prevention; 2. Vegan dietary intervention versus another dietary intervention for primary prevention; 3. Vegan dietary intervention versus another dietary intervention for secondary prevention.
MAIN RESULTS
Thirteen RCTs (38 papers, 7 trial registrations) and eight ongoing trials met our inclusion criteria. Most trials contributed to primary prevention: comparisons 1 (four trials, 466 participants randomised) and comparison 2 (eight trials, 409 participants randomised). We included only one secondary prevention trial for comparison 3 (63 participants randomised). None of the trials reported on clinical endpoints. Other primary outcomes included lipid levels and blood pressure. For comparison 1 there was moderate-certainty evidence from four trials with 449 participants that a vegan diet probably led to a small reduction in total cholesterol (mean difference (MD) -0.24 mmol/L, 95% confidence interval (CI) -0.36 to -0.12) and low-density lipoprotein (LDL) cholesterol (MD -0.22 mmol/L, 95% CI -0.32 to -0.11), a very small decrease in high-density lipoprotein (HDL) levels (MD -0.08 mmol/L, 95% CI -0.11 to -0.04) and a very small increase in triglyceride levels (MD 0.11 mmol/L, 95% CI 0.01 to 0.21). The very small changes in HDL and triglyceride levels are in the opposite direction to that expected. There was a lack of evidence for an effect with the vegan dietary intervention on systolic blood pressure (MD 0.94 mmHg, 95% CI -1.18 to 3.06; 3 trials, 374 participants) and diastolic blood pressure (MD -0.27 mmHg, 95% CI -1.67 to 1.12; 3 trials, 372 participants) (low-certainty evidence). For comparison 2 there was a lack of evidence for an effect of the vegan dietary intervention on total cholesterol levels (MD -0.04 mmol/L, 95% CI -0.28 to 0.20; 4 trials, 163 participants; low-certainty evidence). There was probably little or no effect of the vegan dietary intervention on LDL (MD -0.05 mmol/L, 95% CI -0.21 to 0.11; 4 trials, 244 participants) or HDL cholesterol levels (MD -0.01 mmol/L, 95% CI -0.08 to 0.05; 5 trials, 256 participants) or triglycerides (MD 0.21 mmol/L, 95% CI -0.07 to 0.49; 5 trials, 256 participants) compared to other dietary interventions (moderate-certainty evidence). We are very uncertain about any effect of the vegan dietary intervention on systolic blood pressure (MD 0.02 mmHg, 95% CI -3.59 to 3.62)  or diastolic blood pressure (MD 0.63 mmHg, 95% CI -1.54 to 2.80; 5 trials, 247 participants (very low-certainty evidence)). Only one trial (63 participants) contributed to comparison 3, where there was a lack of evidence for an effect of the vegan dietary intervention on lipid levels or blood pressure compared to other dietary interventions (low- or very low-certainty evidence). Four trials reported on adverse events, which were absent or minor.
AUTHORS' CONCLUSIONS
Studies were generally small with few participants contributing to each comparison group. None of the included studies report on CVD clinical events. There is currently insufficient information to draw conclusions about the effects of vegan dietary interventions on CVD risk factors. The eight ongoing studies identified will add to the evidence base, with all eight reporting on primary prevention. There is a paucity of evidence for secondary prevention.

Identifiants

pubmed: 33629376
doi: 10.1002/14651858.CD013501.pub2
pmc: PMC8092640
doi:

Substances chimiques

Triglycerides 0
Cholesterol 97C5T2UQ7J

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD013501

Informations de copyright

Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Am J Clin Nutr. 2009 May;89(5):1588S-1596S
pubmed: 19339401
Front Nutr. 2019 Apr 17;6:47
pubmed: 31058160
J Nutr. 2011 Aug;141(8):1469-74
pubmed: 21653575
Nutrition. 2004 Sep;20(9):738-46
pubmed: 15325679
Lancet. 2010 Jul 10;376(9735):112-23
pubmed: 20561675
BMJ Open Diabetes Res Care. 2018 Oct 30;6(1):e000534
pubmed: 30487971
Proc Nutr Soc. 2016 Aug;75(3):287-93
pubmed: 26707634
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Am J Health Promot. 2015 Mar-Apr;29(4):245-54
pubmed: 24524383
Am J Med. 2005 Sep;118(9):991-7
pubmed: 16164885
Nutrients. 2019 Mar 13;11(3):
pubmed: 30871233
BMJ Open. 2014 Feb 05;4(2):e003505
pubmed: 24500611
Nutrients. 2018 Feb 09;10(2):
pubmed: 29425120
Am J Med. 2019 Jul;132(7):875-883.e7
pubmed: 30851264
Nutrients. 2017 Sep 15;9(9):
pubmed: 28926931
Obesity (Silver Spring). 2007 Sep;15(9):2276-81
pubmed: 17890496
Perm J. 2019;23:
pubmed: 31634108
Br J Nutr. 2001 Feb;85(2):137-9
pubmed: 11242480
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
J Acad Nutr Diet. 2018 Jun;118(6):1072-1079
pubmed: 29398571
Nutr Res. 2014 Jun;34(6):552-8
pubmed: 25026923
World Health Organ Tech Rep Ser. 2003;916:i-viii, 1-149, backcover
pubmed: 12768890
J Am Diet Assoc. 2008 Oct;108(10):1636-45
pubmed: 18926128
J Am Diet Assoc. 2009 Feb;109(2):263-72
pubmed: 19167953
Eat Behav. 2015 Dec;19:33-8
pubmed: 26164391
Mult Scler Relat Disord. 2016 Sep;9:80-90
pubmed: 27645350
Br J Rheumatol. 1998 Mar;37(3):274-81
pubmed: 9566667
Eur J Clin Nutr. 2013 Oct;67(10):1066-71
pubmed: 23942177
Nutrients. 2018 Sep 14;10(9):
pubmed: 30223451
J Cardiopulm Rehabil. 2004 Jul-Aug;24(4):229-35
pubmed: 15286527
Circulation. 2014 Jun 24;129(25 Suppl 2):S102-38
pubmed: 24222017
Arch Intern Med. 2009 Jun 8;169(11):1046-54
pubmed: 19506174
Prev Med. 1999 Aug;29(2):87-91
pubmed: 10446033
Nutr Diabetes. 2018 Nov 2;8(1):58
pubmed: 30405108
Contemp Clin Trials Commun. 2017 Dec;8:90-98
pubmed: 29333503
J Am Heart Assoc. 2018 Dec 4;7(23):e011367
pubmed: 30571591
Crit Rev Food Sci Nutr. 2017 Nov 22;57(17):3640-3649
pubmed: 26853923
Diabetes Care. 2011 Jul;34(7):1481-6
pubmed: 21593294
Nutr Diabetes. 2015 May 26;5:e158
pubmed: 26011582
Nutrition. 2015 Feb;31(2):350-8
pubmed: 25592014
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
PLoS One. 2018 Dec 20;13(12):e0209086
pubmed: 30571724
Nutr Diabetes. 2017 Mar 20;7(3):e256
pubmed: 28319109
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
Lancet. 2019 Feb 2;393(10170):447-492
pubmed: 30660336
Urology. 2008 Dec;72(6):1319-23
pubmed: 18602144
PLoS One. 2016 Jun 02;11(6):e0155918
pubmed: 27253526
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
Diabetes Care. 2006 Aug;29(8):1777-83
pubmed: 16873779
Eur J Clin Nutr. 2013 Jul;67(7):718-24
pubmed: 23695207
Contemp Clin Trials. 2020 Jan;88:105897
pubmed: 31743793
Cochrane Database Syst Rev. 2021 Feb 25;2:CD013501
pubmed: 33629376
Proc Natl Acad Sci U S A. 2016 Apr 12;113(15):4146-51
pubmed: 27001851

Auteurs

Karen Rees (K)

Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

Lena Al-Khudairy (L)

Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.

Andrea Takeda (A)

Cochrane ENT, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Saverio Stranges (S)

Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH